

| | | |
|-----------|--|----|
| 1.6.5.1.1 | Angiostatin | 23 |
| 1.6.5.1.2 | Endostatin | 23 |
| 1.6.5.2 | Drugs that block endothelial cell proliferation | 24 |
| 1.6.5.3 | VEGF Inhibitors | 25 |
| 1.6.6 | Thalidomide | 26 |
| 1.6.7 | Lenalidomide | 27 |
| 1.6.8 | Linomide | 28 |
| 1.6.9 | Veliparib, ABT-888 | 29 |
| 1.6.10 | Bevacizumab (Avastin) | 30 |
| 1.7 | Aim of investigation | 31 |
| | Chapter two | 33 |
| 2 | Materials and methods | 34 |
| 2.1 | Chemicals | 34 |
| 2.2 | Instrumentation | 34 |
| 2.3 | Methods and Experimental molecular docking | 34 |
| 2.4 | Synthesis of 2-methyl-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole (AZ-1) | 37 |
| 2.5 | Synthesis of: 2-methyl-1-[4-(amino-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole AZ2-AZ7 | 39 |
| 2.5.1 | Preparation of 1-[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]-2-methyl-2,3-dihydro-1H-indole (AZ-2) | 42 |
| 2.5.2 | Preparation of 2-methyl-1-[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-3) | 43 |
| 2.5.3 | Preparation of 2-methyl-1-[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-4) | 44 |
| 2.5.4 | Preparation of 2-methyl-1-[4-(piperidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-5) | 45 |
| 2.5.5 | Preparation of 2-methyl-1-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-6) | 46 |
| 2.5.6 | Preparation of 1-[4-(azepan-1-yl)but-2-yn-1-yl]-2-methyl-2,3-dihydro-1H-indole (AZ-7) | 47 |